Head and Neck Cancer Clinical Trial
Official title:
An Exploratory Study to Assess the Feasibility of Incorporating PET/MR in the Radiotherapy Pathway of Patients With Head and Neck Cancer and Guide Adaptive Dose Escalation
NCT number | NCT02952625 |
Other study ID # | RJ116/N013 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | April 1, 2016 |
Est. completion date | August 1, 2017 |
Verified date | August 2019 |
Source | Guy's and St Thomas' NHS Foundation Trust |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a pilot non-intervention study that aims to introduce PET/MRI, a state of the art new
imaging technique, into the radiotherapy treatment pathway of patients with head and neck
cancer. Ultimately the investigators aim to establish appropriate scanning and image
registration protocols, to allow progression to a randomized trial of adaptive radiotherapy
dose escalation. The latter is thought to potentially improve outcomes in this group.
Ten patients with squamous cell carcinoma (SCC) of the oropharynx, hypopharynx and larynx,
planned for radical treatment with radiotherapy (+/-chemotherapy), will be recruited. Study
participants will have two PET/MRI scans, with the radiotherapy immobilization devices in
situ. The first will be done prior to the start of radiotherapy, the second half way through
treatment.
Image quality will be assessed by comparing to standard diagnostic scans and different
registration methods will be compared to establish the best way of incorporating PET/MR image
data into the radiotherapy planning system. Patient tolerability and workflow considerations
will also be qualitatively assessed. Furthermore, a planning study will be conducted to
establish relevant treatment protocols for a subsequent dose escalation trial.
PET/MRI is an exciting new technology with a lot of potential in the context of adaptive
radiotherapy dose escalation. Within this pilot study the investigators aim to address the
technical challenges of using it in this context prior to proceeding to a randomized trial.
Status | Completed |
Enrollment | 8 |
Est. completion date | August 1, 2017 |
Est. primary completion date | August 1, 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Written, voluntary, informed consent - Age = 18 - Eastern Cooperative Oncology Group (ECOG) Performance Status = 2 - Life expectancy > 12 months - Histologically proven SCC of the oropharynx, hypopharynx and larynx - Radical radiotherapy +/- chemotherapy indicated as the primary treatment modality - Visible disease (>1cm) at the primary site on any imaging modality performed within 4 weeks of starting radiotherapy treatment - Staging PET/CT and diagnostic MRI of the head and neck images need to be available for comparison. - Adequate organ function and absence of other major concurrent illness, allowing the patient to tolerate scanning regime Exclusion Criteria: - Inability to provide informed consent - Impaired renal function (serum creatinine of > 200) - Severely impaired liver function - Patients with allergies or contra-indications to the radio-tracer and/or contrast agent used in the study - Severe claustrophobia or inability to tolerate PET or MRI scans - General contra-indications to MRI, as defined in MRI safety departmental protocols - Serious inter-current conditions or other non-malignant illnesses that are uncontrolled or whose control may be affected by participation in this study - Any patient who has urinary or faecal incontinence - ECOG Performance Status = 3 - Pregnant or breastfeeding women |
Country | Name | City | State |
---|---|---|---|
United Kingdom | Guy's & St Thomas' NHS Foundation Trust | London |
Lead Sponsor | Collaborator |
---|---|
Guy's and St Thomas' NHS Foundation Trust |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of scans where image quality is sufficient to characterise the primary tumour, assessed qualitatively by an experienced radiologist and oncologist | 6 months following study completion | ||
Primary | Proportion of patients that tolerated the full scanning protocol, assessed by tailored patient questionnaire | 6 months following study completion |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05808920 -
The RESCUE Study: Survival and Functional Outcomes Following Salvage Surgery for RESidual or reCurrent sqUamous cEll Carcinoma of the Head and Neck
|
||
Completed |
NCT02526017 -
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
|
Phase 1 | |
Active, not recruiting |
NCT05060432 -
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT03997643 -
Preservation of Swallowing in Respected Oral Cavity Squamous Cell Carcinoma: Examining Radiation Volume Effects (PRESERVE): A Randomized Trial
|
Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT04700475 -
Effect of Low Level Laser Therapy on Prevention of Radiotherapy Induced Xerostomia in Cancer Patients.
|
N/A | |
Withdrawn |
NCT04058145 -
AMD3100 Plus Pembrolizumab in Immune Checkpoint Blockade Refractory Head and Neck Squamous Cell Carcinoma
|
Phase 2 | |
Completed |
NCT02572869 -
Functional and Aesthetic Outcomes After Mandible Reconstruction With Fibula Osteomyocutaneous Free Flaps
|
||
Active, not recruiting |
NCT04474470 -
A Study to Evaluate NT219 Alone and in Combination With ERBITUX® (Cetuximab) in Adults With Advanced Solid Tumors and Head and Neck Cancer
|
Phase 1/Phase 2 | |
Withdrawn |
NCT05073809 -
Photoacoustic Imaging of Head and Neck Tumours
|
||
Active, not recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
Active, not recruiting |
NCT03651570 -
Randomized Controlled Trial of a E-intervention to Help Patients Newly Diagnosed With Cancer Cope Better: Pilot Study
|
N/A | |
Recruiting |
NCT04930432 -
Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06016699 -
Immunological Function After Radiation With Either Proton or Photon Therapy
|
||
Terminated |
NCT03843554 -
Commensal Oral Microbiota in Head and Neck Cancer
|
N/A | |
Recruiting |
NCT05915572 -
Mulligan Technique on Shoulder Dysfunction
|
N/A | |
Completed |
NCT05897983 -
Tens and Rocabado Exercises on TMJ Dysfunction
|
N/A | |
Not yet recruiting |
NCT06289049 -
Heavy Strength Training in Head and Neck Cancer Survivors
|
Phase 2 | |
Withdrawn |
NCT05263648 -
Virtual Reality Software to Reduce Stress in Cancer Patients
|
N/A | |
Withdrawn |
NCT03238638 -
A Study of Epacadostat + Pembrolizumab in Head and Neck Cancer Patients, Who Failed Prior PD-1/PD-L1 Therapy
|
Phase 2 |